

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7606495

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
SCHRODINGER, INC.	09/16/2022
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	SCHRODINGER, LLC
<b>Street Address:</b>	120 WEST 45TH STREET, 17TH FLOOR
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10036
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17971844
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(202)293-7860
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	2022937060
<b>Email:</b>	aquiroa@sughrue.com, sughrue@sughrue.com
<b>Correspondent Name:</b>	SUGHRUE MION, PLLC
<b>Address Line 1:</b>	2000 PENNSYLVANIA AVENUE NW
<b>Address Line 4:</b>	WASHINGTON, D.C. 20006
<b>ATTORNEY DOCKET NUMBER:</b>	Q278477
<b>NAME OF SUBMITTER:</b>	ARI QUIROA
<b>SIGNATURE:</b>	/ARI QUIROA/
<b>DATE SIGNED:</b>	10/24/2022
<b>Total Attachments: 3</b>	
source=Q278477ExecutedAssignmentasfiledfromSchrodingerINCtoSchrodingerLLC#page1.tif	
source=Q278477ExecutedAssignmentasfiledfromSchrodingerINCtoSchrodingerLLC#page2.tif	
source=Q278477ExecutedAssignmentasfiledfromSchrodingerINCtoSchrodingerLLC#page3.tif	

## ASSIGNMENT

**WHEREAS, Schrödinger, Inc.**, a corporation organized under and pursuant to the laws of the United States of America located at 1540 Broadway, 24th Floor, New York 10036, United States of America (hereinafter referred to as “**ASSIGNOR**”), is the owner of right, title, and interest, throughout the world, in and to: (a) the patent applications listed in the attached Schedule A (Scheduled Applications) and the resulting patents, including the right to claim priority from the Scheduled Application (including the national stage entry applications) under international conventions and treaties, (b) any patent applications claiming priority from the Scheduled Application (including the national stage entry applications) under international conventions, treaties, or otherwise, and the patents resulting from the patent applications, and any direct or indirect divisionals, continuations, continuation-in-part applications, and continued prosecution applications (and their relevant international equivalents) of the Scheduled Applications, and the resulting patents; and (c) any patents resulting from reissues, reexaminations, or extensions (and their relevant international equivalents, including, without limitation, supplementary protection certificates) of the patents described in (a) and (b) above, by way of an assignment executed by inventors of above, as shown in the attached executed Assignment;

**WHEREAS, Schrödinger, LLC**, a corporation organized under and pursuant to the laws of the United States of America located at 120 West 45th Street, 17th Floor, New York, New York 10036, United States of America (hereinafter referred to as “**ASSIGNEE**”) desires to acquire the entire right, title, and interest, owned by Schrödinger, Inc., throughout the world, in and to the intellectual property rights to (a) - (c) above.

**NOW, THEREFORE**, for good and valuable consideration, the receipt whereof is hereby acknowledged, **ASSIGNOR** hereby assigns, sells, and transfers to **ASSIGNEE**, its assigns and legal representatives, its entire right, title, and interest, throughout the world, in and to: (a) the intellectual property rights described in Scheduled Applications and the resulting patents, including the right to claim priority from the Scheduled Application (including the national stage entry applications) under international conventions and treaties; (b) any patent applications claiming priority from the Scheduled Applications (including the national stage entry applications) under international conventions, treaties, or otherwise, and the patents resulting from the patent applications, and any direct or indirect divisionals, continuations, continuation-in-part applications, and continued prosecution applications (and their relevant international equivalents) of the Scheduled Applications, and the resulting patents; and (c) any patents resulting from reissues, reexaminations, or extensions (and their relevant international equivalents, including, without limitation, supplementary protection certificates) of the patents described in (a) and (b) above, as a consequence of which **ASSIGNEE**, its assigns and legal representatives have had, held, exercised and enjoyed the entire right, title, and interest in and to the (a), (b), and (c) above, with all the rights, powers, privileges, and advantages arising from or appertaining thereto, for and during the term or terms of said patent applications or patents, for use and benefit of **ASSIGNEE**, its assigns and legal representatives, in as ample and beneficial a manner to all intents and purposes as **ASSIGNOR** might or could have held and enjoyed the

same, if the assignment had not been made.

And, ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks and any other granting authority to issue any patents resulting from the patent applications to ASSIGNEE.

This Agreement may be executed in separate counterparts, each of which shall be identical and may be introduced in evidence or used for any other purpose without any other counterpart, but all of which shall together constitute one and the same agreement. Any such counterparts even if it's executed and/or transmitted electronically via the trusted electronic signature vendor, including scanned signed documents or digital signatures, shall bind the Parties to the same extent as documents with original signatures.

**Schrödinger, Inc.**

Dated: 9/16/22  
By: s/ [Signature]  
Name: [Signature]  
Title: [Signature]

**ACCEPTANCE BY ASSIGNEE**

I hereby accept this assignment on behalf of ASSIGNEE, I declare under penalty of perjury under the laws of the United States of America, and under penalty of the laws of any other jurisdiction before which this document may be presented, that I am an officer of ASSIGNEE, that I have signed this document on behalf of ASSIGNEE, with the full authority of its board of directors, and that all the foregoing is true and correct.

**Schrödinger, LLC**

Dated: 9/16/22  
By: s/ [Signature]  
Name: [Signature]  
Title: [Signature]

### SCHEDULE A

Country	Application No.	Filing Date	Title
PCT	PCT/CN2020/088925	May 7, 2020	COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF
PCT	PCT/CN2021/091843	May 6, 2021	COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF (also "3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF" as appeared in WO2021/223699)
TW	110116409	May 6, 2021	COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF